Factors affecting the benefit of insulin dose intensification in people with Type 2 diabetes: an analysis from the OpT2mise randomized trial

I. Schütz-Fuhrmann, J. Castañeda, Y. Reznik, R. Aronson, I. Conget, S. Liabat, S. Runzis, S. de Portu, O. Cohen

Research output: Contribution to journalLetterpeer-review

4 Scopus citations
Original languageEnglish
Pages (from-to)291-292
Number of pages2
JournalDiabetic Medicine
Volume34
Issue number2
DOIs
StatePublished - 1 Feb 2017
Externally publishedYes

Funding

FundersFunder number
Becton Dickenson
Medtronic International Trading Sàrl
Eli Lilly and Company
Bayer
GlaxoSmithKline
Sanofi
Medtronic
Novo Nordisk

    Cite this